The Food and Drug Administration (FDA) has approved the second drug in a novel new class of cholesterol-lowering drugs. Repatha (evolocumab) is an injectable medication that works by blocking a protein that interferes with the liver’s ability to remove so-called bad cholesterol – or LDL – from the blood. Last month, the FDA approved Praluent (alirocumab), also an injectable drug, was the first medication to be approved from the class, known as PCSK9 inhibitors. The drugs were highly anticipated treatments for patients with dangerously high levels of cholesterol and patients with high cholesterol who cannot tolerate the side effects caused ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.